Stage IIIB Breast Cancer Completed Phase 1 Trials for Lapatinib (DB01259)

IndicationStatusPhase
DBCOND0028549 (Stage IIIB Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01245205Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerTreatment